DREAMS II Study; HPA axis function and sympathetic nervous system activity in survivors of childhood acute lymphoblastic leukemia

DREAMS II Study; HPA axis function and sympathetic nervous system activity in survivors of childhood acute lymphoblastic leukemia - DREAMS II study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37326

Enrollment

Registered

2011-12-19

Start date

2012-01-04

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute lymphoblastic leukemia leukemia

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: All subjects from the VUmc, the UMCU and the UMCN that have been treated according to the Dutch Childhood Oncology Group (DCOG) ALL-9 or ALL-10 protocol and that participated in the DREAMS I study. Healthy age and sex matched controls, existing of: 1) friends of ALL survivors who participate in the DREAMS study, 2) friends of current ALL patients in the VUmc, 3) friends of survivors of childhood cancer who visit the outpatient clinic late effects of the VUmc.

Exclusion criteria

Exclusion criteria: Prolonged glucocorticoid therapy for other reasons than treatment for ALL. Chronic health conditions that might influence HPA axis activity.

Design outcomes

Primary

Measure	Time frame
HPA axis regulation (cortisol) and sympathetic nervous system activity (blood pressure, heart rate) during relaxation and during the Trier social stress test.	—

Secondary

Measure	Time frame
The association between HPA axis activity and sympathetic nervous system activity and fatigue and quality of life.	—

Countries

Netherlands

Outcome results